Rallye Balance Sheet Health
Financial Health criteria checks 0/6
Rallye has a total shareholder equity of €-5.0B and total debt of €3.3B, which brings its debt-to-equity ratio to -64.7%. Its total assets and total liabilities are €18.4B and €23.4B respectively.
Key information
-64.7%
Debt to equity ratio
€3.26b
Debt
Interest coverage ratio | n/a |
Cash | €12.00m |
Equity | -€5.03b |
Total liabilities | €23.42b |
Total assets | €18.38b |
Recent financial health updates
Is Rallye (EPA:RAL) A Risky Investment?
Aug 16Is Rallye (EPA:RAL) A Risky Investment?
Apr 06Here's Why Rallye (EPA:RAL) Has A Meaningful Debt Burden
May 09Recent updates
Here's What To Make Of Rallye's (EPA:RAL) Decelerating Rates Of Return
Jul 10Returns On Capital Are Showing Encouraging Signs At Rallye (EPA:RAL)
Mar 14Rallye's (EPA:RAL) Returns On Capital Are Heading Higher
Sep 27Is Rallye (EPA:RAL) A Risky Investment?
Aug 16Rallye's (EPA:RAL) Returns On Capital Are Heading Higher
May 14Is Rallye (EPA:RAL) A Risky Investment?
Apr 06Rallye (EPA:RAL) Is Doing The Right Things To Multiply Its Share Price
Nov 23Returns Are Gaining Momentum At Rallye (EPA:RAL)
Jun 14Here's Why Rallye (EPA:RAL) Has A Meaningful Debt Burden
May 09Should You Be Impressed By Rallye's (EPA:RAL) Returns on Capital?
Feb 16Are Rallye's (EPA:RAL) Statutory Earnings A Good Reflection Of Its Earnings Potential?
Jan 12Would Shareholders Who Purchased Rallye's (EPA:RAL) Stock Three Years Be Happy With The Share price Today?
Dec 08Financial Position Analysis
Short Term Liabilities: RAL has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: RAL has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: RAL has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: RAL's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Debt Coverage: RAL's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: Insufficient data to determine if RAL's interest payments on its debt are well covered by EBIT.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/23 13:19 |
End of Day Share Price | 2024/12/20 00:00 |
Earnings | 2023/12/31 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Rallye SA is covered by 13 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Nicolas Champ | Barclays |
Laurent Balay | BNP Paribas Exane |
Andrew Gwynn | BNP Paribas Exane |